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Background: S100 proteins are a family of small, EF-hand containing calcium-binding signaling proteins that are
implicated in many cancers. While the majority of human S100 proteins share 25-65% sequence similarity, S100A7
and its recently identified paralog, S100A15, display 93% sequence identity. Intriguingly, however, S100A7 and
S100A15 serve distinct roles in inflammatory skin disease; S100A7 signals through the receptor for advanced
glycation products (RAGE) in a zinc-dependent manner, while S100A15 signals through a yet unidentified G-protein
coupled receptor in a zinc-independent manner. Of the seven divergent residues that differentiate S100A7 and
S100A15, four cluster in a zinc-binding region and the remaining three localize to a predicted receptor-binding
surface.
Results: To investigate the structural and functional consequences of these divergent clusters, we report the X-ray
crystal structures of S100A15 and S100A7D24G, a hybrid variant where the zinc ligand Asp24 of S100A7 has been
substituted with the glycine of S100A15, to 1.7 Å and 1.6 Å resolution, respectively. Remarkably, despite
replacement of the Asp ligand, zinc binding is retained at the S100A15 dimer interface with distorted tetrahedral
geometry and a chloride ion serving as an exogenous fourth ligand. Zinc binding was confirmed using anomalous
difference maps and solution binding studies that revealed similar affinities of zinc for S100A15 and S100A7.
Additionally, the predicted receptor-binding surface on S100A7 is substantially more basic in S100A15 without
incurring structural rearrangement.
Conclusions: Here we demonstrate that S100A15 retains the ability to coordinate zinc through incorporation of an
exogenous ligand resulting in a unique zinc-binding site among S100 proteins. The altered surface chemistry
between S100A7 and S100A15 that localizes to the predicted receptor binding site is likely responsible for the
differential recognition of distinct protein targets. Collectively, these data provide novel insight into the structural
and functional consequences of the divergent surfaces between S100A7 and S100A15 that may be exploited for
targeted therapies.
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The S100 calcium-binding protein family of vertebrate,
metal-regulated proteins plays pivotal roles in a wide
variety of intracellular and extracellular functions includ-
ing cell growth, inflammation, membrane remodeling
and chemotaxis [1,2] and are implicated in many dis-
eases including cancer [3-6]. Hallmarks of the S100 pro-
tein family include their small size (~ 100 aa) and the
presence of a canonical (calmodulin-like) EF-hand motif
and a non-canonical (S100-specific) EF-hand motif [7].
Additional complexity in S100 proteins is derived from
their ability to adopt a non-covalent anti-parallel homo/
heterodimers that can further associate to yield higher
order multimers such as tetramers and hexamers
[3,5,8,9].
While most S100 proteins share moderate sequence
identity, S100A7 and S100A15 are 93% identical in se-
quence yet intriguingly display divergent functions.
S100A7, for example, is implicated in inflammatory skin
diseases and in several cancers including breast cancer
[4,10-13] where it is associated with aggressive estrogen
receptor negative tumors and poor prognosis [14,15].
Intracellular S100A7 has also been shown to interact
with the multifunctional signaling protein Jab1, resulting
in translocation of Jab1 to the nucleus where it mediates
S100A7 tumorigenic effects [16,17]. While S100A15 is
also highly expressed in psoriatic lesions [18,19], it dis-
plays distinct localizations in skin and breast, divergent
functions in epithelial maturation and skin inflammation
[19,20] and it is currently unknown whether S100A15
contributes to breast cancer progression [21]. S100A7
and S100A15 are also capable of binding different sur-
face receptors [5]. S100A7 interacts with RAGE (recep-
tor for advanced glycated end products) to mediate
chemotaxis of leukocytes [20,22] while S100A15 appears
to mediate chemotaxis through an unidentified G pro-
tein coupled receptor [20].
The ability of many S100 proteins to coordinate zinc is
central to their function [23]. For example, the ability of
S100A7 to engage RAGE and exert antimicrobial effects
are both dependent on zinc [20] [24]. These observa-
tions suggest a regulatory role although the zinc coord-
ination geometry and affinity suggest a structural role
[25]. It is not yet known whether zinc binding plays a
structural or regulatory role in S100A7 and S100A15
function. To our knowledge, there is no data to suggest
S100A15 function is zinc-dependent. Thus far, two types
of S100-family zinc sites have been proposed [23]. In the
first type (‘His-Zn’), the zinc is coordinated by 3 histi-
dines and an aspartate (i.e. S100A7 and S100A12) or
with four histidines (i.e. S100B). The second type (‘Cys-
Zn’) is proposed to contain primarily cysteines as the
zinc-coordinating residues though no structure of an
S100 ‘Cys-Zn’ binding site has been reported. Ultimatelydefining the zinc binding capacity for S100A15 is crucial
to understanding its function and appropriately categor-
izing it within the S100 family of proteins. To this end,
we report the structural characterization of S100A15
and an Asp24Gly variant of S100A7 to 1.7 Å and 1.6 Å,
respectively. These data reveal an unexpected structural
compensation to retain zinc binding in S100A15 and a
structural rationale for the inability of S100A15 to co-
ordinate RAGE and the prediction that S100A15 will
not bind Jab1.Methods
Protein production and purification
S100A15 (S100A7 template with the following substitu-
tions - D24G, R21G, D27E, N51H, T52I, D56T, T83A)
and S100A7 D24G were generated using using Quik-
change mutagenesis (Stratagene) of wildtype S100A7
[10] and recombinantly produced as a thioredoxin fu-
sion with an N-terminal hexa histidine tag. Protein pro-
duction was performed in E. coli Rosetta-Gammi B in
Overnight Express™ Instant TB Medium (Novagen)
overnight at 37°C. The cells were harvested, resus-
pended in binding buffer (20 mM HEPES pH 8, 30 mM
imidazole, 1 M NaCl, and 50 μM zinc chloride), lysed
using a French press, applied to a His-trap column and
eluted using an increasing gradient of imidazole to
500 mM. Fractions were analyzed with SDS-PAGE,
pooled based on purity, concentrated and the histidine
tag removed by thrombin digestion prior to a final puri-
fication step using superdex Sx75 gel filtration column.
Due to the absence of Tryptophan or phenylalanine
residues, protein concentration was calculated based on
amino acid analysis.Crystallization, data collection, processing and structure
solution
Crystallization was performed at 18 °C using the sitting
drop vapour diffusion method. S100A15 was crystallized
at 26 mg/ml in 45–50 mM zinc acetate dihydrate, 18-20
% PEG 3350 and S100A7D24G was crystallized at
19 mg/ml in 0.2 M ammonium sulfate, 0.1 M BisTris pH
5.5, 20-25% PEG 3350. Diffraction data were collected
on beamline 9–2 at SSRL and processed with d*trek
[26]. Data collection and refinement statistics are pre-
sented in Table 1. Refinement was performed with the
CCP4 suite of programs [27]. The initial phases were
obtained by molecular replacement (MR) using MOL-
REP [28] with the monomeric form of native S100A7.
Solvent atoms were selected using COOT [29] and the
structure refined with REFMAC [28]. Stereo-chemical
analysis of the refined structures was performed with
PROCHECK and SFCHECK in CCP4 [27]. Overall 5% of
the reflections were set aside for calculation of Rfree.
Table 1 Data collection and refinement statistics
A. Data collection S100A15 S100A7D24G
Spacegroup I2 P43212
a, b, c (Å) 52.03, 33.47, 64.05 51.48, 51.48, 117.23
α, β, γ (deg.) 90, 90.81, 90 90, 90, 90
Wavelength 0.9794 0.9794
Resolution range (Å) 40.66-1.70 (1.79-1.70) 38.68-1.60 (1.69-1.60)
Measured reflections 44302 203068
Unique reflections 12285 21100
Redundancy 3.6 (3.6) 9.6 (9.8)
Completeness (%) 99.6 (100.0) 99.6 (98.4)
I/σ(I) 8.7 (2.5) 15.3 (2.6)
Rmerge
a 0.071 (0.385) 0.048 (0.430)
B. Refinement
Resolution (Å) 28.15-1.70 (1.74-1.70) 34.76-1.60 (1.64-1.60)
Rcryst
b 0.199 (0.313) 0.190 (0.250)
Rfree














Bond lengths (Å) 0.013 0.016
Bond angles (deg.) 1.321 1.533
Ramachandran statistics
Most favoured 97.87 98.91
Allowed 2.13 1.09
Disallowed 0 0
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Coordinates and structure factor accession codes are as
follows: S100A15 (4AQI, r4aqisf ) and S100A7D24G
(4AQJ, r4aqjsf ).
Results and discussion
S100A15 retains the ability to coordinate zinc
To investigate the differences in zinc binding between
S100A7 and S100A15, we recombinantly produced
human S100A15 in E. coli and purified the protein to
homogeneity using nickel affinity chromatography.Similar to S100A7, S100A15 eluted as a stable dimer
from a size exclusion column (SEC) indicating that the
seven divergent residues (R21G, D24G, D27E, T83A,
T51I, N52H and D56T – S100A7 residues are shown in
italics and S100A15 residues are underlined) (Figure 1A)
did not disrupt the multimeric structure. S100A15 crys-
tallized as a monomer in the asymmetric unit of the
monoclinic cell with the dimer generated by crystallo-
graphic symmetry (Figure 1B). Molecular replacement
was used to solved the S100A15 structure with native
S100A7 [9] as the search model and all waters, zinc and
calcium ions removed and the 7 divergent residues
(highlighted as yellow triangles and green diamonds in
Figure 1A and B) mutated to alanine. The S100A15
structure was refined to a resolution of 1.7 Å and dis-
played an overall root mean squared deviation (r.m.s.d)
of 0.661 Å2 over 96 Cα atoms relative to S100A7.
During the initial refinement stages of the S100A15
structure an 8 sigma difference electron density peak
was observed that overlaid with the bound zinc in
S100A7 (Figure 1C). Accordingly, a zinc ion was mod-
eled and refined at full occupancy resulting in a B-factor
of 30.52 Å2. Thus, it was apparent that substitution of
Gly24 in S100A15 for the zinc ligand Asp24 (S100A7)
did not abrogate zinc binding. Remarkably, the coordin-
ation geometry of the three histidine ligands (His86 and
His90 - monomer 2) and His17 - monomer 1)
(Figure 1C) is virtually unchanged between S100A7
(109°±9°) and S100A15 (109°±3°). Of these ligands, only
His90 displayed a measurable shift with a 15° reorienta-
tion and a shift of the imidazole ring NE2 and ND1 by
1.1 Å and 2.2 Å, respectively, likely due to the position
of His90 on a mobile surface loop (Figure 1B – black
arrow). To complete the distorted tetrahedral geometry
of the bound zinc in S100A15, a chloride ion was mod-
eled, which refined to a distance of 2.1 Å from the zinc
and a B factor of 25.4 Å2. While water molecules are
commonly observed as labile ligands in zinc coordin-
ation sites, we elected to model a chloride ion using the
B factor as a guide and based on the fact that chloride
was the dominant anion in our buffer. While Asp24 has
been previously observed as a bindentate ligand [30], we
measured Zn-O bond distance of 2.04 Å (OD1) and
2.69 Å (OD2). The shorter bond length between Zn and
Asp24 OD1 suggests that S100A7 Asp 24 likely acts as a
monodentate ligand, and that both S100A15 and
S100A7 bind zinc in a 4 coordinate geometry. In support
of the relevance of the observed zinc coordination by
S100A15, we obtained preliminary isothermal titration
calorimetry data by 1) treating with Chelex resin to re-
move zinc and 2) back-titrating with ZnCl2, to allow dir-
ect measurement of binding. These preliminary results
show nearly identical dH values of −12.3 ± 0.1 kcal/mol
and −12.1 ± 0.1 kcal/mol for S100A7 and S100A15,
Figure 1 S100A15 binds zinc with distorted tetrahedral geometry. A. Sequence alignment of S100A15 (NP_789793.1), S100A7 (CAG46961.1),
S100A12 (NP_005612.1) and S100B (CAG46920.1). Divergent residues between S100A15 and S100A7 are denoted as yellow triangles (zinc binding
cluster) and green diamonds (predicted receptor binding cluster). B. Surface representation of S100A15 with one monomer shown in sky blue
and the other in orange. Black arrow in the right panel denotes the flexibility of the surface loop to which the His90 zinc ligand is attached. C.
Left panel – Fo-Fc electron density of the zinc binding site of S100A15 calculated at 1.5 sigma with zinc shown as a grey sphere and the chloride
ligand shown as a yellow sphere. Right panel – Anomalous difference electron density map of S100A7D24G using data collected at the zinc edge
of 1.2482 nm calculated at 5 sigma confirming that the bound metal is zinc. All figures were generated with PyMol.
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ation by both proteins in spite of the change of coordin-
ation environment. Zn affinities determined by ITC
(~109 M–1 for S100A7, and 4 x 108 M–1 for S100A15)
vary depending on buffer composition, but are generally
within five-fold of each other under a given set ofconditions. The construction of pseudopolarograms on
S100A7 and S100A15 samples using anodic stripping
voltammetry, and the analysis of resulting half-wave po-
tential shifts also indicate that both proteins bind zinc
with similar affinity [31]. Full solution-phase data will be
reported in due course.
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is sufficient to produce a zinc-binding site unique among
S100 proteins
To confirm that the substitution of Asp24 with a glycine
was solely responsible for the unique zinc-binding site
observed in S100A15, we generated the D24G variant of
S100A7. S100A7D24G eluted as a dimer from the SEC,
and crystallized with one monomer in the asymmetric
unit of the tetragonal cell. Diffraction data was collected
to a resolution of 1.6 Å (Table 1) and the structure
solved by molecular replacement. The S100A7D24G and
S100A15 structures aligned closely with an r.m.s.d of
0.719 Å over 96 Cα atoms. Subtle adjustments were
observed in the orientation of the histidine ligands, due
to differential packing of surface loops between the
monoclinic and tetragonal crystal forms. To validate the
modeling of zinc at the dimer interface, we calculated an
anomalous difference map using data collected at the
zinc edge of 1.2482 nm. A large anomalous difference
peak (>12 σ) was observed where the zinc had been
modeled confirming the identity of the bound metal as
zinc (Figure 1C – right panel). While crystallization of
S100A15 was completed in the presence of zinc,
S100A7D24G was crystallized in the absence of zinc,
and yet zinc binding was observed in the same geometry.Figure 2 Zinc binding in S100 proteins. A. Comparison of zinc binding
panel) and S100A12 (lower panel). Note the unique strategy employed in S
coordination geometry of the bound zinc. B. Structural divergence betwee
surface highlighted by the black arrows representing the three divergent reThese observations indicate that the zinc-binding
observed in the S100A15 is not an artifact. Similar to
S100A15, a chloride ion was modeled as the exogenous
fourth ligand to complete the distorted tetrahedral
geometry. The incorporation of a dissociable ligand such
as chloride may enable a binding partner to donate a
fourth ligand thereby ensuring a tighter ligand-receptor
complex. A second zinc atom was observed in the
S100A15 structure (at Glu36), which was not observed
in the S100A7D24G mutant. We expect this is an
artifact as S100A15 WT was crystallized in high concen-
trations (50 mM) of zinc while S100A7D24G was crys-
tallized in the absence of zinc.
Analysis of zinc binding sites between S100A15,
S100A7, S100B and S100A12 reveal highly conserved
coordination geometry for the metal positioned at the
dimer interface. While sequence analysis shows that
S100A12 and S100B encode a glycine at the equivalent
sequence (Figure 1A) position to 24 in S100A15, a
three-residue insertion (relative to S100A15 and A7)
results in a histidine (S100B) or an aspartate (S100A12)
being correctly positioned to serve as the fourth zinc lig-
and (Figure 2). Thus, it appears that multiple different
strategies are used by S100 proteins to maintain the dis-
torted coordination geometry of the zinc bound at thesites between S100A15 and S100A7 (upper panel), S100B (middle
100A15 to incorporate an exogenous ligand to complete the distorted
n S100A15 and S100A7 localized to the predicted receptor-binding
sidues. Note the decreased acidity in S100A15.
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In fact, the strict conservation of the zinc site is remark-
able especially in the context of structural divergences
relative to S100A15 (r.m.s.d for S100B of 0.802 Å over
118 Cα atoms, and S100A12 of 2.109 Å over 113 Cα
atoms) with substantial reorganization in nearby surface
loops (Figure 2A). It is not clear why the zinc binding af-
finities of rat S100B (0.094 μM) and human S100A12
(4.5 μM) are much higher than human S100A7
(100 μM) [32-34].Altered surface chemistry on S100A15 may explain the
lack of RAGE and predicted Jab1 binding
The second cluster of amino acid differences (T51I,
N52H and D56T - S100A7 residues are shown in italics
and S100A15 residues are underlined) between S100A7
and S100A15 is localized to an ordered loop between
helices IIb and III and extending into the N-terminal
portion of helix III. The center of this cluster is posi-
tioned approximately 24 Å from the closest zinc-binding
site. Intriguingly, this region in S100A7 has been impli-
cated in mediating interaction with Jab1 [8,9,17] and be-
tween S100B and RAGE [35]. The inability of S100A15
to bind RAGE [20], and the prediction that S100A15
lacks a functional Jab1 binding site [8,36], suggests that
this localized cluster of residues is a hot spot surface for
ligand-receptor interactions in the S100 family of pro-
teins. Functional consequences based on altered second-
ary structure have been observed in S100A7 where
mutation of Asp56 to Gly resulted in shortening of helix
III [8]. However, no such changes were observed in
S100A15 and overlay of helix III (amino acids 50–62) of
S100A7 and S100A15 yielded an r.m.s.d of only 0.219 Å
over 9 Cα atoms. Overall, the replacement of Asp56 with
Thr and Asn52 with His substantially alters the surface
chemistry and may explain the inability of S100A15 to
bind RAGE.
Despite being capable of specific interactions with
unique targets, the emerging data on S100-RAGE interac-
tions suggest that S100 proteins have evolved to also inter-
act with a common receptor, RAGE, via unique structural
binding sites and in distinct multimeric states [35,37-39].
Adding to the combinatorial possibilities of S100-RAGE
interactions is the observation that the RAGE is capable
of multimerization: S100B tetramers interact with RAGE
dimers, S100B dimers interact with RAGE monomers
[40], and S100A12 hexamers interact with RAGE tetra-
mers [37,38]. However, close examination of the amino
acid sequences and structures of S100B, S100A12, S100A7
and S100A15 (Figures 1A and 2B) offers little to explain
why S100A15 does not bind RAGE while other S100 pro-
teins do. Extensive scanning mutagenesis or structural
characterization of the complexes will ultimately berequired to define the core features that promote macro-
molecular assembly.
Conclusions
Zinc-coordination is a dynamic process and can play a
role in the regulation of protein function [25]. Recent
studies have suggested that misregulation of zinc
homeostasis is associated with cancer [41]. Distinct
metal binding and protein-interacting functions have
been described for S100A7 and S100A15 despite their
93% sequence identity. Zinc is required for several
S100A7 functions, including antimicrobial action and
RAGE binding. S100A15 does not bind RAGE and a
zinc-dependent function has not yet been identified,
which has led to the suggestion that S100A15 does not
bind zinc. Here we demonstrate that S100A15 does in
fact coordinate zinc in a distorted tetrahedral geometry
with an exogenous ligand that is unique to S100 pro-
teins. These data place S100A15 as the first member of
what is likely to be a growing subgroup of S100 proteins.
Further studies are required to establish the mechanism
of receptor interactions with the S100 proteins, but di-
vergent solutions to maintain zinc binding is undoubt-
edly going to play a central role.
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